Total Payments
$151,717
2024 Payments
$35.18
Companies
22
Transactions
230
Medicare Patients
1,317
Medicare Billing
$509,689
Payment Breakdown by Category
Other$113,430 (74.8%)
Travel$17,607 (11.6%)
Consulting$14,625 (9.6%)
Food & Beverage$5,985 (3.9%)
Education$69.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $113,430 | 32 | 74.8% |
| Travel and Lodging | $17,607 | 56 | 11.6% |
| Consulting Fee | $14,625 | 6 | 9.6% |
| Food and Beverage | $5,985 | 133 | 3.9% |
| Education | $69.99 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Kite Pharma, Inc. | $143,516 | 152 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $2,569 | 4 | $0 (2021) |
| TG THERAPEUTICS, INC. | $1,987 | 5 | $0 (2021) |
| PFIZER INC. | $1,642 | 4 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $951.59 | 16 | $0 (2021) |
| Shire North American Group Inc | $152.65 | 2 | $0 (2018) |
| Celgene Corporation | $143.95 | 8 | $0 (2021) |
| ABBVIE INC. | $108.67 | 6 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $95.85 | 5 | $0 (2019) |
| Gilead Sciences, Inc. | $70.68 | 3 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.18 | 2 | ABBVIE INC. ($35.18) |
| 2023 | $28,765 | 27 | Kite Pharma, Inc. ($28,738) |
| 2022 | $65,754 | 68 | Kite Pharma, Inc. ($65,698) |
| 2021 | $2,488 | 14 | TG THERAPEUTICS, INC. ($1,987) |
| 2020 | $2,227 | 4 | Kite Pharma, Inc. ($2,214) |
| 2019 | $26,230 | 44 | Kite Pharma, Inc. ($25,641) |
| 2018 | $21,766 | 54 | Kite Pharma, Inc. ($21,181) |
| 2017 | $4,452 | 17 | Pharmacyclics LLC, An AbbVie Company ($2,500) |
All Payment Transactions
230 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $17.65 | General |
| Category: ONCOLOGY | ||||||
| 09/06/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $17.53 | General |
| Category: ONCOLOGY | ||||||
| 11/10/2023 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $26.33 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $680.00 | General |
| Category: CELLT | ||||||
| 07/11/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,690.00 | General |
| Category: CELLT | ||||||
| 06/21/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,690.00 | General |
| Category: CELLT | ||||||
| 06/16/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,250.00 | General |
| Category: CELLT | ||||||
| 05/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $67.58 | General |
| Category: CELLT | ||||||
| 05/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $51.30 | General |
| Category: CELLT | ||||||
| 05/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: CELLT | ||||||
| 05/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: CELLT | ||||||
| 05/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: CELLT | ||||||
| 05/19/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $396.64 | General |
| Category: CELLT | ||||||
| 05/19/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $303.97 | General |
| Category: CELLT | ||||||
| 05/19/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $51.29 | General |
| Category: CELLT | ||||||
| 04/25/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,740.00 | General |
| Category: CELLT | ||||||
| 04/25/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $39.75 | General |
| Category: CELLT | ||||||
| 04/24/2023 | Kite Pharma, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,740.00 | General |
| 04/21/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $40.48 | General |
| 04/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $143.14 | General |
| Category: CELLT | ||||||
| 04/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $124.85 | General |
| Category: CELLT | ||||||
| 04/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $113.45 | General |
| Category: CELLT | ||||||
| 04/20/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $38.00 | General |
| Category: CELLT | ||||||
| 04/18/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $786.94 | General |
| 04/18/2023 | Kite Pharma, Inc. | — | Travel and Lodging | In-kind items and services | $622.19 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 68 | 139 | $34,853 | $10,095 |
| 2021 | 14 | 373 | 5,430 | $767,034 | $216,354 |
| 2020 | 30 | 876 | 19,693 | $891,196 | $283,241 |
Total Patients
1,317
Total Services
25,262
Medicare Billing
$509,689
Procedure Codes
48
All Medicare Procedures & Services
48 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 81 | $21,837 | $6,485 | 29.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 20 | 25 | $9,760 | $2,884 | 29.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 11 | $3,080 | $660.22 | 21.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 18 | 22 | $176.00 | $66.00 | 37.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2021 | 14 | 4,320 | $577,440 | $153,059 | 26.5% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 61 | 259 | $69,153 | $21,603 | 31.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 44 | 102 | $38,501 | $14,679 | 38.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 42 | 64 | $17,920 | $6,067 | 33.9% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2021 | 25 | 48 | $17,616 | $5,911 | 33.6% |
| 96401 | Non-hormonal anti-neoplastic chemotherapy beneath the skin or into muscle | Office | 2021 | 22 | 51 | $10,506 | $3,484 | 33.2% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis up to 1 hour | Office | 2021 | 34 | 54 | $10,044 | $3,238 | 32.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 16 | 16 | $8,528 | $2,794 | 32.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 13 | 13 | $6,734 | $2,128 | 31.6% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 15 | 16 | $4,400 | $1,285 | 29.2% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis | Office | 2021 | 18 | 60 | $3,420 | $1,103 | 32.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 45 | 213 | $1,704 | $639.00 | 37.5% |
| 96375 | Injection of different drug or substance into a vein for therapy, diagnosis, or prevention | Office | 2021 | 12 | 18 | $774.00 | $253.99 | 32.8% |
| J3475 | Injection, magnesium sulfate, per 500 mg | Office | 2021 | 12 | 196 | $294.00 | $108.49 | 36.9% |
| J9145 | Injection, daratumumab, 10 mg | Office | 2020 | 11 | 2,730 | $371,280 | $119,893 | 32.3% |
| J9047 | Injection, carfilzomib, 1 mg | Office | 2020 | 11 | 2,520 | $236,880 | $74,189 | 31.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 57 | 246 | $65,682 | $20,923 | 31.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 41 | 119 | $45,113 | $13,078 | 29.0% |
| 96413 | Infusion of chemotherapy into a vein up to 1 hour | Office | 2020 | 57 | 112 | $41,104 | $13,010 | 31.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 36 | 74 | $20,720 | $6,000 | 29.0% |
| J9025 | Injection, azacitidine, 1 mg | Office | 2020 | 11 | 4,800 | $12,030 | $3,642 | 30.3% |
About Dr. Peter Mcsweeney, MD
Dr. Peter Mcsweeney, MD is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/06/2005. The National Provider Identifier (NPI) number assigned to this provider is 1881678449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Mcsweeney, MD has received a total of $151,717 in payments from pharmaceutical and medical device companies, with $35.18 received in 2024. These payments were reported across 230 transactions from 22 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($113,430).
As a Medicare-enrolled provider, Mcsweeney has provided services to 1,317 Medicare beneficiaries, totaling 25,262 services with total Medicare billing of $509,689. Data is available for 3 years (2020–2022), covering 48 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Denver, CO
- Active Since 12/06/2005
- Last Updated 06/22/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1881678449
Products in Payments
- Yescarta (Drug) $126,185
- Imbruvica (Drug) $2,540
- UKONIQ (Drug) $1,987
- KYMRIAH (Biological) $777.66
- ONCASPAR (Biological) $152.65
- Tavalisse (Drug) $62.63
- EMPLICITI (Biological) $62.02
- Marqibo (Drug) $50.00
- VENCLEXTA (Biological) $49.49
- Venclexta (Drug) $47.16
- VENCLEXTA (Drug) $43.86
- Pomalyst (Drug) $42.47
- Idhifa (Drug) $42.35
- NOXAFIL (Drug) $42.16
- SARCLISA (Biological) $35.91
- VYXEOS (Drug) $33.93
- SPRYCEL (Drug) $33.83
- JAKAFI (Drug) $30.45
- IMBRUVICA (Drug) $29.49
- BOSULIF (Drug) $28.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068
Peter Forsberg, Md, MD
Hematology & Oncology — Payments: $98,100
Hematology & Oncology $98,100